Open in Screener

ADMA

Adma Biologics Inc

Aug 29 • 04:00PM ET

17.26

Dollar change -0.12
Percentage change -0.69	%

Healthcare • Biotechnology • USA • NASD

Peers: CSL GRFS BAX BMY PFE JNJ MRK LLY COHR GILD

| Held by: IJR VTI IWM XBI VB VXF SPSM IJT IWO VBK

Index	RUT	P/E	20.32	EPS (ttm)	0.85	Insider Own	3.43%	Shs Outstand	239.38M	Perf Week	-3.03%
Market Cap	4.12B	Forward P/E	19.04	EPS next Y	0.91	Insider Trans	-6.73%	Shs Float	230.45M	Perf Month	-7.70%
Enterprise Value	4.11B	PEG	0.67	EPS next Q	0.15	Inst Own	89.27%	Short Float	6.49%	Perf Quarter	-13.00%
Income	208.93M	P/S	8.69	EPS this Y	18.27%	Inst Trans	3.28%	Short Ratio	4.91	Perf Half Y	5.31%
Sales	474.17M	P/B	10.37	EPS next Y	57.23%	ROA	44.70%	Short Interest	14.96M	Perf YTD	0.64%
Book/sh	1.66	P/C	45.62	EPS next 5Y	30.15%	ROE	71.23%	52W High	25.67 -32.76%	Perf Year	-0.52%
Cash/sh	0.38	P/FCF	62.62	EPS past 3/5Y	- -	ROIC	43.43%	52W Low	13.50 27.85%	Perf 3Y	536.90%
Dividend Est.	-	EV/EBITDA	25.14	Sales past 3/5Y	74.01% 70.79%	Gross Margin	52.98%	Volatility	2.60% 4.69%	Perf 5Y	501.39%
Dividend TTM	-	EV/Sales	8.67	EPS Y/Y TTM	491.01%	Oper. Margin	32.82%	ATR (14)	0.69	Perf 10Y	89.01%
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	43.58%	Profit Margin	44.06%	RSI (14)	46.86	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	5.33	EPS Q/Q	3.93%	SMA20	-0.88%	Beta	0.53	Target Price	32.33
Payout	0.00%	Debt/Eq	0.21	Sales Q/Q	13.80%	SMA50	-2.78%	Rel Volume	0.83	Prev Close	17.38
Employees	685	LT Debt/Eq	0.21	Earnings	Aug 06 AMC	SMA200	-7.89%	Avg Volume	3.05M	Price	17.26
IPO	Oct 17, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.75% 0.18%	Trades		Volume	2,526,688	Change	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-23	Resumed	Raymond James	Strong Buy	$5
Oct-13-22	Initiated	Mizuho	Buy	$5
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy	$5
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jun-04-19	Initiated	Jefferies	Buy	$8
Apr-15-19	Reiterated	H.C. Wainwright	Buy	$10 → $13
Feb-07-19	Resumed	H.C. Wainwright	Buy	$10
Dec-11-17	Reiterated	Maxim Group	Buy	$13 → $8
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy	$13
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy	$24 → $14
May-13-15	Reiterated	Maxim Group	Buy	$18 → $24
Dec-08-14	Initiated	Oppenheimer	Outperform	$20
Dec-01-14	Reiterated	Maxim Group	Buy	$16 → $18

Show Previous Ratings

Aug-27-25 09:58AM	ADMA Biologics, Inc. (ADMA): A Bull Case Theory (Insider Monkey)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -9.65%
08:17AM	ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum (Zacks)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:03PM	Adma Biologics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 09:32AM	ADMA Biologics Inc (ADMA) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-30-25 05:45PM	Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note (Zacks)
07:00AM	ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-29-25 05:50PM	Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts (Zacks)
Jul-24-25 09:30AM	Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet (Zacks)
Jul-23-25 11:00AM	Heavy Insider Selling at ADMA Biologics Despite Earnings Strength (Insider Monkey)
Jul-21-25 05:50PM	Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jul-15-25 05:50PM	Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors (Zacks)
Jul-09-25 05:50PM	Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know (Zacks)
09:30AM	Loading…
Jul-08-25 09:30AM	Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? (Zacks)
Jun-27-25 05:50PM	Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
10:56AM	Implied Volatility Surging for ADMA Biologics Stock Options (Zacks)
08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-25-25 08:54AM	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? (Zacks)
Jun-24-25 10:21AM	ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios (Insider Monkey)
Jun-20-25 05:50PM	Here's Why Adma Biologics (ADMA) Fell More Than Broader Market (Zacks)
Jun-19-25 02:05PM	ADMA Biologics (ADMA) Drops for 5th Consecutive Day - Here's Why (Insider Monkey)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 06:20AM	Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now? (Zacks)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-05-25 06:20AM	Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar? (Zacks)
10:01AM	Loading…
May-28-25 10:01AM	ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? (Zacks)
May-22-25 08:34AM	Are Options Traders Betting on a Big Move in ADMA Biologics Stock? (Zacks)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks) -5.75%
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks) -10.21%
12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks)
12:25PM	Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits (Investor's Business Daily)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
03:30AM	ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-07-25 11:05PM	ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates (Zacks)
04:30PM	Adma Biologics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:29AM	Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up (Zacks)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
May-06-25 01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks)
12:50PM	3 Mid-Cap Medical Stocks Outperforming the Market (MarketBeat)
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
09:17AM	RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-05-25 08:25AM	Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus (Zacks)
May-02-25 05:45PM	Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks)
11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
May-01-25 01:22PM	Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? (Zacks)
10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:40AM	Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? (Zacks)
09:00AM	Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know (Zacks)
08:50AM	Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why (Zacks)
07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
04:51AM	The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:24AM	These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date (Zacks)
07:00AM	ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-29-25 05:50PM	Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
08:45AM	Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth (GlobeNewswire)
02:01AM	Why ADMA Biologics, Inc. (ADMA) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval (Investor's Business Daily) +12.12%
07:00AM	ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process (GlobeNewswire)
Apr-25-25 01:52PM	Tech Stocks Reclaim Dominance In Elite List Led By Palantir (Investor's Business Daily)
10:41AM	GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline (Zacks)
Apr-24-25 11:54AM	BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook (Zacks)
Apr-23-25 08:48PM	ADMA Biologics, Inc. (ADMA): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
06:14PM	Is ADMA Biologics, Inc. (ADMA) the Best Multibagger Stock to Buy According to Billionaires? (Insider Monkey)
05:50PM	Adma Biologics (ADMA) Gains But Lags Market: What You Should Know (Zacks)
Apr-22-25 01:28AM	Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday? (Insider Monkey) +8.91%
Apr-17-25 05:50PM	Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks) -7.84%
09:17AM	GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP (Zacks)
09:09AM	ADMA Biologics (ADMA): Among Louis Navellier's New Stock Picks (Insider Monkey)
Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks)
09:30AM	Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks)
06:45AM	Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? (Insider Monkey)
Apr-15-25 12:27PM	VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study (Zacks) +5.93%
10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks)
09:40AM	Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? (Zacks)
09:35AM	Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average (Zacks)
09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks)

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grossman Adam S	President and CEO	Aug 15 '25	Option Exercise	5.40	15,000	81,000	2,052,850	Aug 15 09:00 PM
Grossman Adam S	President and CEO	Aug 15 '25	Sale	16.88	21,000	354,480	2,031,850	Aug 15 09:00 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Jul 30 '25	Option Exercise	8.98	2,500	22,450	489,898	Aug 01 09:00 PM
Grossman Adam S	President and CEO	Jul 15 '25	Option Exercise	5.40	15,000	81,000	2,058,850	Jul 16 09:00 PM
Grossman Adam S	President and CEO	Jul 15 '25	Sale	18.66	21,000	391,860	2,037,850	Jul 16 09:00 PM
Grossman Adam S	Director and Officer	Jul 15 '25	Proposed Sale	18.68	63,000	1,176,840		Jul 15 09:01 PM
Grossman Adam S	President and CEO	Jun 16 '25	Option Exercise	5.40	15,000	81,000	2,064,850	Jun 18 09:00 PM
Grossman Adam S	President and CEO	Jun 16 '25	Sale	20.81	21,000	437,010	2,043,850	Jun 18 09:00 PM
ELMS STEVE	Director	Jun 13 '25	Option Exercise	3.43	332,680	1,140,763	420,010	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 16 '25	Sale	20.24	194,749	3,941,720	87,330	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 13 '25	Sale	20.82	137,931	2,871,723	282,079	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 12 '25	Sale	21.69	92,941	2,015,890	2,031,730	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 12 '25	Proposed Sale	21.87	425,621	9,308,331		Jun 12 08:33 PM
Guiheen Lawrence P.	Director	Jun 09 '25	Sale	20.96	20,000	419,200	94,830	Jun 11 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Option Exercise	5.00	10,000	50,000	488,194	Jun 10 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Sale	21.31	10,000	213,100	478,194	Jun 10 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Proposed Sale	20.61	10,000	206,100		Jun 09 09:00 PM
Lawrence P Guiheen Rev Tr DTD	Director	Jun 04 '25	Proposed Sale	20.75	20,000	415,000		Jun 04 01:52 PM
Guiheen Lawrence P.	Director	May 21 '25	Option Exercise	5.96	7,779	46,363	122,609	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 22 '25	Option Exercise	5.96	1,221	7,277	116,051	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 21 '25	Sale	20.32	7,779	158,069	114,830	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 22 '25	Sale	20.12	1,221	24,567	114,830	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 21 '25	Proposed Sale	20.44	9,000	183,960		May 21 09:36 PM
Grossman Adam S	President and CEO	May 15 '25	Option Exercise	5.40	15,000	81,000	2,070,850	May 16 09:00 PM
Grossman Adam S	President and CEO	May 15 '25	Sale	19.45	21,000	408,450	2,049,850	May 16 09:00 PM
Grossman Adam S	President and CEO	Apr 15 '25	Option Exercise	5.40	15,000	81,000	2,076,850	Apr 16 09:00 PM
Grossman Adam S	President and CEO	Apr 15 '25	Sale	21.46	21,000	450,660	2,055,850	Apr 16 09:00 PM
Grossman Adam S	President and CEO	Mar 19 '25	Option Exercise	5.40	15,000	81,000	2,082,850	Mar 21 09:00 PM
Grossman Adam S	President and CEO	Mar 19 '25	Sale	18.92	21,000	397,320	2,061,850	Mar 21 09:00 PM
Grossman Adam S	Director and Officer	Mar 19 '25	Proposed Sale	18.71	84,000	1,571,640		Mar 19 09:40 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Jan 30 '25	Option Exercise	10.80	5,000	54,000	449,587	Feb 03 09:00 PM
ELMS STEVE	Director	Nov 27 '24	Option Exercise	10.80	9,000	97,200	2,124,671	Dec 02 09:02 PM
Tade Brad L.	CFO and Treasurer	Nov 22 '24	Sale	21.15	15,000	317,250	199,433	Nov 22 09:05 PM
Grossman Adam S	President and CEO	Nov 22 '24	Sale	21.10	48,967	1,033,204	1,989,007	Nov 22 09:05 PM
Grossman Adam S	Director and Officer	Nov 22 '24	Proposed Sale	21.30	48,967	1,042,997		Nov 22 09:00 PM
Tade Brad L.	Officer	Nov 22 '24	Proposed Sale	21.30	15,000	319,500		Nov 22 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Option Exercise	10.80	9,000	97,200	162,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Sale	18.47	9,000	166,189	153,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Proposed Sale	16.26	9,000	146,340		Sep 09 09:00 PM

Open in Screener

MRKR

Marker Therapeutics Inc

Aug 29 • 04:00PM ET

0.9257

Dollar change +0.0296
Percentage change 3.30	%

Healthcare • Biotechnology • USA • NASD

MRKR Marker Therapeutics Inc daily Stock Chart

Peers: NVAX IOVA ALLO ADAP KPTI TVRD MGNX AGEN CERS TXMD

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	28.91%	Shs Outstand	11.30M	Perf Week	-28.24%
Market Cap	11.98M	Forward P/E	-	EPS next Y	-1.73	Insider Trans	0.00%	Shs Float	9.20M	Perf Month	-33.88%
Enterprise Value	0.17M	PEG	-	EPS next Q	-0.36	Inst Own	9.76%	Short Float	3.87%	Perf Quarter	-40.66%
Income	-14.61M	P/S	2.22	EPS this Y	-26.18%	Inst Trans	-27.68%	Short Ratio	0.18	Perf Half Y	-39.50%
Sales	5.39M	P/B	1.00	EPS next Y	-15.52%	ROA	-110.48%	Short Interest	0.36M	Perf YTD	-70.23%
Book/sh	0.93	P/C	1.01	EPS next 5Y	7.97%	ROE	-144.68%	52W High	5.95 -84.44%	Perf Year	-74.43%
Cash/sh	0.91	P/FCF	-	EPS past 3/5Y	39.79% 23.96%	ROIC	-139.25%	52W Low	0.81 14.30%	Perf 3Y	-71.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	74.44% 98.63%	Gross Margin	-	Volatility	16.10% 9.81%	Perf 5Y	-94.74%
Dividend TTM	-	EV/Sales	0.03	EPS Y/Y TTM	-17.92%	Oper. Margin	-272.41%	ATR (14)	0.14	Perf 10Y	-98.29%
Dividend Ex-Date	-	Quick Ratio	3.45	Sales Y/Y TTM	44.55%	Profit Margin	-271.11%	RSI (14)	32.00	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	-17.00%	SMA20	-20.92%	Beta	1.50	Target Price	6.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-26.35%	SMA50	-33.94%	Rel Volume	0.30	Prev Close	0.90
Employees	5	LT Debt/Eq	0.00	Earnings	Aug 18	SMA200	-50.54%	Avg Volume	1.96M	Price	0.93
IPO	Jan 05, 1998	Option/Short	No / Yes	EPS/Sales Surpr.	18.10% 104.51%	Trades		Volume	590,597	Change	3.30%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Initiated	Canaccord Genuity	Buy	$8
Mar-25-21	Initiated	Piper Sandler	Overweight	$6
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight	$6
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $2.50
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

Aug-28-25 08:00AM	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-27-25 12:02PM	Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study (Insider Monkey) -6.01%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.63%
07:00AM	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma (GlobeNewswire)
Jul-30-25 08:00AM	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:30AM	Loading…
Jul-17-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.00%
Jun-17-25 08:00AM	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma (GlobeNewswire)
May-20-25 08:00AM	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma (GlobeNewswire)
May-19-25 08:00AM	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies (GlobeNewswire)
Apr-01-25 08:00AM	Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference (GlobeNewswire) -7.32%
Mar-31-25 08:45AM	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Dec-19-24 08:06AM	Marker Therapeutics Announces $16.1 Million Private Placement (GlobeNewswire) -7.44%
08:05AM	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma (GlobeNewswire)
Dec-17-24 07:00AM	Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer (GlobeNewswire) +17.68%
08:30AM	Loading…
Dec-10-24 08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann and Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
Nov-26-24 11:00AM	Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit (GlobeNewswire)
Nov-14-24 04:30PM	Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -12.29%
Oct-22-24 08:20AM	Marker Therapeutics price target raised to $19 from $11 at Ladenburg (TipRanks) +22.70%
Sep-26-24 02:33PM	AML cell therapy trials to watch in 2024 targeting GvHD (Clinical Trials Arena) +6.59%
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-14-24 04:30PM	Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -5.41%
Aug-12-24 07:00AM	Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma (GlobeNewswire)
Jun-28-24 11:52AM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.42%
May-15-24 11:53PM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:15PM	Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-08-24 07:00AM	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies (GlobeNewswire)
Mar-25-24 05:45PM	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results (GlobeNewswire) -10.74%
Mar-22-24 12:30PM	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.82%
07:30AM	Loading…
Jan-22-24 07:30AM	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601 (GlobeNewswire) +5.56%
Jan-08-24 09:31AM	Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization (Benzinga)
08:24AM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization (GlobeNewswire)
Dec-21-23 11:00AM	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-11-23 07:00AM	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse (GlobeNewswire) +46.85%
Nov-09-23 05:00PM	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.56%
Sep-11-23 07:00AM	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse (GlobeNewswire) +11.41%
Aug-30-23 08:00AM	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +6.75%
Aug-25-23 12:07PM	Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) -5.52%
Aug-17-23 09:03AM	Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies (Newsfile)
Aug-14-23 04:30PM	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +25.75%
Aug-07-23 07:00AM	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program (GlobeNewswire)
Jul-26-23 07:00AM	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 (GlobeNewswire)
Jul-22-23 08:12AM	Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95% (Simply Wall St.)
Jul-10-23 07:00AM	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients (GlobeNewswire) +23.04%
Jun-26-23 07:00AM	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration (GlobeNewswire) -6.59%
Jun-12-23 07:00AM	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial (GlobeNewswire) +19.52%
May-31-23 06:30AM	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells (GlobeNewswire) +33.84%
May-17-23 06:11AM	Marker Therapeutics First Quarter 2023 Earnings: US$0.57 loss per share (vs US$1.19 loss in 1Q 2022) (Simply Wall St.)
May-08-23 07:30AM	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer (GlobeNewswire) +15.97%
May-01-23 07:30AM	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady (GlobeNewswire) +16.47%
Mar-22-23 08:10AM	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results (GlobeNewswire) -31.82%
Dec-13-22 07:23PM	Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund (American City Business Journals)
07:00AM	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million (GlobeNewswire)
Nov-22-22 07:28AM	Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely (Simply Wall St.)
07:00AM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Nov-10-22 05:35PM	MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Marker Therapeutics Reports Q3 2022 Operating and Financial Results (GlobeNewswire)
Sep-13-22 07:00AM	Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Markers Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML (GlobeNewswire) +7.12%
Sep-08-22 07:00AM	Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire) +31.50%
Aug-11-22 04:22PM	Marker Therapeutics Reports Q2 2022 Operating and Financial Results (GlobeNewswire) -8.08% -12.24%
Aug-04-22 04:37PM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma (GlobeNewswire) +63.64%
Jun-15-22 07:06AM	Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky (Simply Wall St.)
May-13-22 07:00AM	Marker Therapeutics Reports Q1 2022 Operating and Financial Results (GlobeNewswire)
May-04-22 10:30AM	Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting (GlobeNewswire) +8.00%
Apr-26-22 07:00AM	Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf (GlobeNewswire)
Mar-17-22 05:45PM	Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-07-22 04:05PM	Marker Therapeutics to Present at Two Upcoming March Investor Conferences (GlobeNewswire) +8.86%
Feb-17-22 01:08PM	Why Are Marker Therapeutics Shares Trading Lower On Thursday? (Benzinga) -25.99%
Feb-16-22 04:30PM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion (GlobeNewswire)
Feb-08-22 04:05PM	Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 (GlobeNewswire)
Jan-20-22 06:38AM	Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer (Benzinga) -10.67%
Jan-19-22 04:49PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer (GlobeNewswire)
Jan-06-22 08:53AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.) -5.51%
Dec-31-21 09:40AM	Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock? (Zacks)
Dec-09-21 07:00AM	Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors (PR Newswire)
Nov-18-21 04:05PM	Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting (PR Newswire) -7.35%
Nov-10-21 04:05PM	Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results (PR Newswire)
Oct-08-21 09:24AM	Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR) (Simply Wall St.)
Sep-07-21 04:05PM	Marker Therapeutics to Present at Three Upcoming September Investor Conferences (PR Newswire)
Aug-20-21 12:00PM	38 Stocks Moving In Friday's Mid-Day Session (Benzinga) +8.33%
Aug-19-21 04:05PM	Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas (PR Newswire) -5.08%
Aug-10-21 04:01PM	Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results (PR Newswire)
Aug-09-21 06:57AM	Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-28-21 04:05PM	Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility (PR Newswire)
Jul-06-21 07:00AM	Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML (PR Newswire)
Jun-29-21 09:01AM	Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock? (Insider Monkey)
Jun-16-21 04:05PM	Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference (PR Newswire)
May-20-21 04:06AM	Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation (Simply Wall St.) +5.44%
May-12-21 04:05PM	Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results (PR Newswire) -8.47%
02:45PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Apr-29-21 04:05PM	Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 (PR Newswire)
Apr-27-21 07:41PM	Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (PR Newswire) +8.91%
Apr-08-21 03:23PM	Study shows wearables could detect COVID-19 earlier (Yahoo Finance Video) +6.31%
Apr-07-21 08:32AM	Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't? (Zacks) -8.85%
Mar-16-21 04:57PM	Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock (PR Newswire)
Mar-15-21 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Mar-12-21 08:00AM	Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire) -23.32%
Mar-11-21 04:10PM	Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
Mar-09-21 04:12PM	Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results (PR Newswire) +6.81%

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELMS STEVE	Director	Dec 23 '24	Buy	3.20	11,085	35,472	325,370	Dec 26 04:01 PM
New Enterprise Associates 16,	10% Owner	Dec 23 '24	Buy	3.20	554,250	1,773,600	1,625,678	Dec 23 04:40 PM

ADMA

Adma Biologics Inc

MRKR

Marker Therapeutics Inc

Upgrade your FINVIZ experience